Efficacy of intramuscular injection of Xiyanping injection for the treatment of acute bronchitis in children: a multicenter, randomized, parallel-controlled clinical study
CHEN Qiang, ZHU Xiao-Hua, LIU Yang, LI Lan, LUO Jing-Hua, ZHANG Yan-Yan, HUANG Juan, CAO Xiao-Chun, SONG Xiao-Hua, WAN Fang-Rui
Department of Respiratory Medicine, Jiangxi Provincial Children's Hospital, Nanchang 330000, China
Abstract Objective To study the efficacy and safety of Xiyanping injection through intramuscular injection for the treatment of acute bronchitis in children. Methods A prospective study was conducted from December 2021 to October 2022, including 78 children with acute bronchitis from three hospitals using a multicenter, randomized, parallel-controlled design. The participants were divided into a test group (conventional treatment plus Xiyanping injection; n=36) and a control group (conventional treatment alone; n=37) in a 1:1 ratio. Xiyanping injection was administered at a dose of 0.3 mL/(kg·d) (total daily dose ≤8 mL), twice daily via intramuscular injection, with a treatment duration of ≤4 days and a follow-up period of 7 days. The treatment efficacy and safety were compared between the two groups. Results The total effective rate on the 3rd day after treatment in the test group was significantly higher than that in the control group (P<0.05), while there was no significant difference in the total effective rate on the 5th day between the two groups (P>0.05). The rates of fever relief, cough relief, and lung rale relief in the test group on the 3rd day after treatment were higher than those in the control group (P<0.05). The cough relief rate on the 5th day after treatment in the test group was higher than that in the control group (P<0.05), while there was no significant difference in the fever relief rate and lung rale relief rate between the two groups (P>0.05). The cough relief time, daily cough relief time, and nocturnal cough relief time in the test group were significantly shorter than those in the control group (P<0.05), while there were no significant differences in the fever duration and lung rale relief time between the two groups (P>0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05). Conclusions The overall efficacy of combined routine treatment with intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children is superior to that of routine treatment alone, without an increase in the incidence of adverse reactions.
CHEN Qiang,ZHU Xiao-Hua,LIU Yang et al. Efficacy of intramuscular injection of Xiyanping injection for the treatment of acute bronchitis in children: a multicenter, randomized, parallel-controlled clinical study[J]. CJCP, 2023, 25(11): 1107-1112.
CHEN Qiang,ZHU Xiao-Hua,LIU Yang et al. Efficacy of intramuscular injection of Xiyanping injection for the treatment of acute bronchitis in children: a multicenter, randomized, parallel-controlled clinical study[J]. CJCP, 2023, 25(11): 1107-1112.
Che S, Zhou N, Liu Y, et al. Andrographolide exerts anti-respiratory syncytial virus activity by up-regulating heme oxygenase-1 independent of interferon responses in human airway epithelial cells[J]. Mol Biol Rep, 2023, 50(5): 4261-4272. PMID: 36918433. PMCID: PMC10013987. DOI: 10.1007/s11033-023-08346-z.
Gu X, Gao R, Li Y, et al. Combination effect of azithromycin with TCM preparation Xiyanping injection against Klebsiella pneumoniae infection in rats[J]. Phytomedicine, 2022, 104: 154332. PMID: 35853301. DOI: 10.1016/j.phymed.2022.154332.
Peng S, Gao J, Liu W, et al. Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-κB signaling and NLRP3 inflammasome activation[J]. Oncotarget, 2016, 7(49): 80262-80274. PMID: 27793052. PMCID: PMC5348318. DOI: 10.18632/oncotarget.12918.
Guo W, Liu W, Chen G, et al. Water-soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-κB pathways[J]. Int Immunopharmacol, 2012, 14(4): 613-619. PMID: 23036579. DOI: 10.1016/j.intimp.2012.09.002.
Gao F, Liu X, Shen Z, et al. Andrographolide sulfonate attenuates acute lung injury by reducing expression of myeloperoxidase and neutrophil-derived proteases in mice[J]. Front Physiol, 2018, 9: 939. PMID: 30174607. PMCID: PMC6107831. DOI: 10.3389/fphys.2018.00939.
